Joseph Maakaron

15PUBLICATIONS
121CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Transplantation immunologyHaematological tumoursHaematologyGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Feb 04, 2026
A phase 1/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed/refractory AML after allogeneic HCT.

Muhammad Umair Mushtaq, John F DiPersio, Jacques Azzi

|Oct 23, 2025
Remission of TP53-Mutant AML After Transplantation With Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Followed by a Donor-Derived Anti-CD33 Chimeric Antigen Receptor T (VCAR33).

Guenther Koehne, Muhammad U Mushtaq, Lori S Muffly

|Oct 22, 2024
Siltuximab for chimeric antigen receptor T-cell therapy-related CRS and ICANS: a multicenter retrospective analysis.

Amneet Bajwa, Qiuhong Zhao, Marcus Geer

|May 15, 2024
Chimeric antigen receptor T-cell infusion for large B-cell lymphoma in complete remission: a center for international blood and marrow transplant research analysis.

Trent P Wang, Kwang W Ahn, Mazyar Shadman

|Nov 17, 2023
Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy.

Madiha Iqbal, Deepa Jagadeesh, Julio Chavez

|Jul 19, 2023
Nicotinamide enhances natural killer cell function and yields remissions in patients with non-Hodgkin lymphoma.

Frank Cichocki, Bin Zhang, Cheng-Ying Wu

Pageof 3

Frequent Collaborators

6 joint publications

Daniel Weisdorf

4 joint publications

Veronika Bachanova

4 joint publications

Marcos de Lima

3 joint publications

Mohamed A Kharfan-Dabaja